AEON Biopharma (AEON) Competitors $1.01 +0.09 (+10.11%) Closing price 03:59 PM EasternExtended Trading$1.02 +0.01 (+1.18%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AEON vs. PLUR, MRSN, LIMN, SONN, SNTI, MURA, EGRX, ATHE, RANI, and ITRMShould you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Pluri (PLUR), Mersana Therapeutics (MRSN), Liminatus Pharma (LIMN), Sonnet BioTherapeutics (SONN), Senti Biosciences (SNTI), Mural Oncology (MURA), Eagle Pharmaceuticals (EGRX), Alterity Therapeutics (ATHE), Rani Therapeutics (RANI), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. AEON Biopharma vs. Its Competitors Pluri Mersana Therapeutics Liminatus Pharma Sonnet BioTherapeutics Senti Biosciences Mural Oncology Eagle Pharmaceuticals Alterity Therapeutics Rani Therapeutics Iterum Therapeutics Pluri (NASDAQ:PLUR) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Which has stronger earnings and valuation, PLUR or AEON? Pluri has higher revenue and earnings than AEON Biopharma. Pluri is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$1.34M27.38-$22.58M-$5.17-0.87AEON BiopharmaN/AN/A-$36.63M-$6.08-0.17 Do insiders & institutionals believe in PLUR or AEON? 16.6% of Pluri shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 25.9% of Pluri shares are owned by insiders. Comparatively, 0.9% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is PLUR or AEON more profitable? AEON Biopharma has a net margin of 0.00% compared to Pluri's net margin of -1,701.19%. AEON Biopharma's return on equity of 0.00% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-1,701.19% -4,191.91% -88.27% AEON Biopharma N/A N/A -994.63% Do analysts prefer PLUR or AEON? Pluri currently has a consensus price target of $12.00, indicating a potential upside of 167.56%. Given Pluri's higher possible upside, equities research analysts clearly believe Pluri is more favorable than AEON Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00AEON Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, PLUR or AEON? Pluri has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Does the media favor PLUR or AEON? In the previous week, Pluri had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for Pluri and 1 mentions for AEON Biopharma. Pluri's average media sentiment score of 0.00 equaled AEON Biopharma'saverage media sentiment score. Company Overall Sentiment Pluri Neutral AEON Biopharma Neutral SummaryPluri beats AEON Biopharma on 7 of the 13 factors compared between the two stocks. Get AEON Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEON vs. The Competition Export to ExcelMetricAEON BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.80M$982.62M$9.05B$10.60BDividend YieldN/A4.84%5.69%4.71%P/E Ratio5.631.2585.8527.35Price / SalesN/A141.72535.75201.60Price / CashN/A17.6437.9261.55Price / Book-0.257.3613.056.78Net Income-$36.63M-$7.88M$3.30B$275.79M7 Day Performance24.22%28.56%4.79%2.63%1 Month Performance35.34%30.25%9.97%9.12%1 Year Performance-98.75%-7.69%85.15%35.86% AEON Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEONAEON Biopharma1.0134 of 5 stars$1.01+10.1%N/A-99.1%$11.80MN/A5.635Analyst ForecastGap UpPLURPluri1.7217 of 5 stars$4.61-0.9%$12.00+160.3%-13.0%$37.93M$1.34M-0.89150News CoverageAnalyst ForecastGap UpMRSNMersana Therapeutics3.9807 of 5 stars$7.79+2.9%$56.60+626.6%-81.0%$37.78M$40.50M-0.53150Analyst ForecastLIMNLiminatus PharmaN/A$1.67+15.2%N/AN/A$37.72MN/A0.00N/APositive NewsEarnings ReportAnalyst ForecastGap DownSONNSonnet BioTherapeutics1.7427 of 5 stars$4.89-8.3%$20.00+309.0%+5.1%$36.39M$20K0.0010News CoverageAnalyst ForecastGap DownSNTISenti Biosciences1.9627 of 5 stars$1.40+0.7%$8.50+507.1%-25.2%$36.36MN/A-0.164Analyst ForecastMURAMural Oncology2.841 of 5 stars$2.08-0.5%$12.00+476.9%-40.1%$36.21MN/A-0.24119Analyst ForecastEGRXEagle Pharmaceuticals1.4506 of 5 stars$2.70-4.4%N/A+445.5%$35.07M$257.55M0.00100Gap DownATHEAlterity Therapeutics2.5148 of 5 stars$3.93-0.5%$12.00+205.3%+226.5%$35.03MN/A0.0010News CoverageAnalyst ForecastGap UpRANIRani Therapeutics2.6853 of 5 stars$0.49+2.1%$7.33+1,396.6%-77.6%$34.50M$1.20M-0.54110Analyst ForecastGap UpITRMIterum Therapeutics1.485 of 5 stars$0.69-4.8%$9.00+1,213.9%-20.2%$33.96MN/A-0.8110Analyst Forecast Related Companies and Tools Related Companies PLUR Alternatives MRSN Alternatives LIMN Alternatives SONN Alternatives SNTI Alternatives MURA Alternatives EGRX Alternatives ATHE Alternatives RANI Alternatives ITRM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AEON) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
